CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies

OncoImmunology

Volumn 3, Issue 7, 2014, Pages

  Houot, Roch ^a,b   Kohrt, Holbrook ^c  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody dependent cell mediated cytotoxicity (ADCC); Immunotherapy; Monoclonal antibody; Natural killer cells

Indexed keywords

CANCER ANTIBODY; CD137 ANTIBODY; CD137 ANTIGEN; CETUXIMAB; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOCYTE DEPLETION; LYMPHOMA; NATURAL KILLER CELL; NONHUMAN; PASSIVE IMMUNIZATION; TUMOR CELL; VACCINAL EFFECT;

EID: 84911427963     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.941740     Document Type: Article

References (10)

1. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID: 20414205; http://dx.doi.org/10.1038/nri2744
2. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635-42; PMID: 15226177; http://dx.doi.org/10.1182/blood-2004-03-1110
3. Abès R, Gélizé E, Fridman W H, Teillaud J-L. Long-lasting antitumor protection by anti- CD20 antibody through cellular immune response. Blood 2010; 116:926-34; PMID: 20439625; http://dx.doi.org/10.1182/blood-2009-10-248609
4. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich- Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, et al. The therapeutic effect of anti- HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18:160-70; PMID: 20708157; http://dx.doi.org/10.1016/j.ccr.2010.06.014
5. Selenko N, Majdic O, Jäger U, Sillaber C, Stöckl J, KnappW. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J Clin Immunol 2002; 22:124-30; PMID: 12078853; http://dx.doi.org/10.1023/A:1015463811683
6. Srivastava RM, Lee SC, Filho PAA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res OffJ A. Assoc Cancer Res 2013; 19:1858-72; http://dx.doi.org/10.1158/1078-0432.CCR-12-2426
7. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher Jr RJ, Bankert RB, Bernstein SH. Rituximab immunotherapy results in the induction of a lymphoma idiotype- specific T-cell response in patients with follicular lymphoma: support for a 'vaccinal effect' of rituximab. Blood 2009; 113:3809-12; PMID: 19196657; http://dx.doi.org/10.1182/blood-2008-10-185280
8. Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-BarfiI, Marabelle A, Lira R, et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014. http://dx.doi.org/10.1172/JCI73014
9. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, et al. CD137 stimulation enhances the antilymphoma activity of anti- CD20 antibodies. Blood 2011; 117:2423-32; PMID: 21193697; http://dx.doi.org/10.1182/blood-2010-08-301945
10. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng W-K, Clarke MF, Carlson RW, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012; 122:1066-ndash;75; PMID: 22326955; http://dx.doi.org/10.1172/JCI61226